Recent Updates — PURE

Pure Bioscience reported net product sales of $2.315 million for the fiscal year ended July 31, 2026, an increase from $2.198 million in the prior year. The company posted a net loss of $2.5 million compared to $2.4 million previously, driven by increased operating expenses and interest costs despite higher sales across its end-user network. Net cash used in operations was $1.97 million. Pure Bioscience develops and commercializes proprietary antimicrobial products based on patented silver dihydrogen citrate technology, primarily serving the food and beverage industry.

Pure Bioscience, Inc. completed a private placement financing on October 15, 2026, raising $555,000 by issuing 10,183,486 shares of common stock at $0.0545 per share to accredited investors. Board member Tom Y. Lee invested the entire amount directly and through affiliates. Net proceeds are expected to be approximately $555,000 after offering expenses, with funds allocated for general corporate purposes including research and development, administrative expenses, and working capital. The company is a developer of patented non-toxic silver dihydrogen citrate antimicrobial products.